Prognosis at 6 Months for Coronary and Cerebrovascular Patients: Impact of Antiplatelet Agents and Statins: Results from the Prevenir III Study

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cardiovascular Drugs and Therapy

• Publication date

  2006-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10557-006-6561-2PMID 16552472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis

  2005cited by this paper
• Explaining the Decline in Coronary Heart Disease Mortality in England and Wales Between 1981 and 2000

  2004cited by this paper
• [European Guidelines on Cardiovascular Disease Prevention in the Clinical Practice. Third work group of the european societies and other societies on cardiovascular disease prevention in the clinical practice].

  2004cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): is it really practical?

  2004cited by this paper
• Anomalies of the Fetal Venous System: A Report of 26 Cases and Review of the Literature

  2004cited by this paper
• European Guidelines on Cardiovascular Disease Prevention in the Clinical Practice. Third work group of the european societies and other societies on cardiovascular disease prevention in the clinical practice

  2004cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): is it really practical?

  2004cited by this paper
• Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.

  2003cited by this paper
• European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

  2003cited by this paper
• Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

  2003cited by this paper
• Occurrence of Secondary Ischemic Events Among Persons With Atherosclerotic Vascular Disease

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• β-Blockers in the Post–Myocardial Infarction Patient

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• &bgr;-Blockers in the Post-Myocardial Infarction Patient

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• The way I see it: House officers need formal career development

  2002cited by this paper
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

  2002cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Five-Year Survival After First-Ever Stroke and Related Prognostic Factors in the Perth Community Stroke Study

  2000cited by this paper
• Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations.

  2000cited by this paper
• Variations in Stroke Incidence and Survival in 3 Areas of Europe

  2000cited by this paper
• Regular articleRisk Factors and Outcomes for Atherothrombotic Disease in French Patients: The RIVAGE Study☆

  1999cited by this paper
• Risk factors and outcomes for atherothrombotic disease in French patients: the RIVAGE study. RIsque VAsculaire Group d'Etude.

  1999influential reference
• Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper
• Importance of cerebrovascular disease in studies of myocardial infarction.

  1996cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• The Scandinavian Simvastatin Survival Study (4S)

  1995cited by this paper
• Muscle fatigue and dyspnoea in chronic heart failure: two sides of the same coin?

  1995cited by this paper
• Potential role of angiotensin converting enzyme inhibitors in treatment of atherosclerosis.

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group.

  1992cited by this paper

• Statins and the risks of stroke recurrence and death after ischemic stroke: the Fukuoka Stroke Registry.

  2013cites this paper
• Chronic treatment with statins increases the availability of selenium in the antioxidant defence systems of hemodialysis patients.

  2010cites this paper
• Identification of patients at risk of ischemic events for long‐term secondary prevention

  2009cites this paper
• [Statins in coronary patients: a solved issue?].

  2008cites this paper
• Cardiopathie ischémique : le point sur le traitement pharmacologique en 2008

  2008cites this paper
• Statines chez le coronarien : un problème résolu ?

  2008cites this paper
• Statins and clinical outcomes in heart failure.

  2007cites this paper
• POTENTIAL ADVERSE EFFECTS FROM STATINS Lowering cholesterol with statins compared with innately low cholesterol

  2007cites this paper